MEL-001 · Melanoma · BRAF/NRAS/Checkpoint Engine

PHASES

SORRIES

NPs

Molecular Engine + Treatment

BRAF V600E Dabrafenib+Trametinib PROVEN

COMBI-d: OS 25.1mo. BRAF 50% melanoma.

Long 2015 NEJM COMBI-d

Nivolumab+Ipilimumab CheckMate 067 PROVEN

58% 5-yr OS metastatic. ORR 57.6%.

Robert 2015 NEJM

TIL Lifileucel FDA 2024 PROVEN

First TIL therapy approval. ORR 31.5% pretreated.

Sarnaik 2021 J Clin Oncol

Pembrolizumab Adjuvant Stage III PROVEN

RFS 75.4% vs 61.0% at 3yr.

Eggermont 2018 NEJM KEYNOTE-054

BRAF+MEK+PD-1 Triple OPEN

Atezolizumab+vem+cobi. PFS 15.1 vs 10.6mo. Higher toxicity.

Gutzmer 2020 Lancet IMSPIRE150

Open Sorries — Click to Expand

S-1 SORRY-1 · Acquired BRAF Resistance

S-2 SORRY-2 · Uveal Melanoma No Systemic Therapy

S-3 SORRY-3 · Mucosal Melanoma Resistant

S-4 SORRY-4 · BRAF+Checkpoint Combo Toxicity

S-5 SORRY-5 · Checkpoint Biomarker Insufficient

Biomarkers + Signal

See Phases tab for molecular classification details. Key biomarkers noted in phase gates above.

Novel Patterns

Emerging therapies and patterns logged in PEMCLAU v11. See GREYBACK yang case corpus for yin/yang attack-defense mapping.